Cellular Dynamics and the National Eye Institute Establish a Cooperative Research and Development Agreement (CRADA) to Advance Cell Transplantation Therapy for the Treatment of Retinal Degenerative Disease using iPSC-Derived Cells

MADISON, WIS., June 22, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to conduct research to advance a cell transplantation therapy for the treatment of retinal degenerative disease using retinal pigment epithelium derived from induced pluripotent stem cells (iPSC-RPE). The collaboration includes the joint development of an optimized biocompatible biodegradable scaffold that is likely to be a critical component for a potential future therapy.

Key Points

  • CDI will provide manufactured cells (iPSC-RPE and iPSC-endothelial cells) and optimize maintenance and cryopreservation media for iPSC-RPE growing on biodegradable scaffolds.
  • NEI will perform experiments to create functional iPSC-RPE cell tissue on scaffolds and evaluate iPSC-RPE efficacy in animal models. These experiments will also be used to evaluate Fujifilm recombinant peptide (RCP) as a scaffold material and to test methods of cryopreservation.
  • NEI and CDI will perform preclinical studies for HLA-matched iPSCs using established Good Manufacturing Practice (GMP)-compatible protocols with potentially up to five HLA iPSC lines.
  • Both NEI and CDI will guide advancement of the project by exchanging and jointly analyzing the results.
  • One aim of the agreement is for NEI and CDI to create a novel vascularized scaffold for the therapeutic transplantation of iPSC-RPE in ocular diseases, such as age-related macular degeneration.

Read the full press release from Cellular Dynamics here: https://cellulardynamics.com/assets/CDI-NEI-CRADA-FINAL.pdf